Millions of people all over the world suffer from diseases, for which there is no known treatment. At the same time, thousands of skilled scientists are working on early research projects, which might one day provide novel therapies for the people in need.
Herantis Pharma plc. is a specialty pharmaceutical company bridging the gap from bench to bedside, aiming to develop novel pharmaceutical products based on some of the leading scientific research in the world. Our focus is in indications of unmet clinical need such as Dry eye, Parkinson’s disease, and Secondary lymphedema, where we intend to develop selected drug candidates through late preclinical and early clinical stages to reach a clinical Proof-of-Concept.
Herantis’ shares are listed on NASDAQ OMX Helsinki First North Finland.